Table 1 The baseline characteristics of identified studies and recruited patients
Study | Study design | Country | Sample size | Age (years) | BMI (kg/m2) | Basal FSH (IU/L) | LH (IU/L) | LH to FSH ratio | T (ng/ml) | PRL (ng/L) | Total Gn dose (IU) | Peak E2 (pg/ml) | PG (ng/ml) | ADAMTS |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Xiao 2014 [31] | Prospective | China | 40 | 30.5 | 22.7 | 4.6 | 5.4 | 1.2 | 0.7 | 20.7 | 1703 | 3903 | NA | ADAMTS-1: oocyte maturity (r = 0.8857; P = 0.0333); oocyte recovery (r = 0.8857; P = 0.0333); fertilization (r = 0.8313; P = 0.0403); cleavage rate (r = 0.7714; P = 0.1028); good quality embryo rate (r = 0.3714; P = 0.4972) |
Tola 2017 [32] | Prospective | Turkey | 21 | 29.2 | 27.9 | 7.3 | 6.1 | NA | NA | NA | NA | NA | 0.79 | ADAMTS-1: metaphase II oocytes (P > 0.05); implantation (P < 0.05) |
GohariTaban 2019 [33] | Prospective | Iran | 37 | 28.6 | 26.5 | 6.0 | 7.1 | NA | NA | NA | NA | NA | NA | ADAMTS-1: oocyte recovery (r = 0.39; P = 0.03), oocyte maturation (r = 0.48; P = 0.02), fertilization (r = 0.48; P = 0.04); ADAMTS-9: oocyte recovery (r = 0.78; P = 0.006) oocyte maturation (r = 0.32; P = 0.004); fertilization rate (r = 0.38; P = 0.07) |
GohariTaban 2021 [34] | Retrospective | Iran | 35 | 29.1 | 26.3 | 6.8 | 7.1 | NA | NA | NA | NA | NA | NA | ADAMTS-4: oocyte recovery (r = 0.91; P < 0.001), oocyte maturation (r = 0.60; P = 0.001), and fertilization (r = 0.85; P < 0.001); ADAMTS-5: oocyte recovery (r = 0.54; P = 0.008), oocyte maturation (r = 0.66; P < 0.001), and fertilization (r = 0.52; P = 0.010) |
Yang 2021 [35] | Retrospective | China | 48 | 29.5 | 24.9 | 6.0 | 9.7 | NA | 0.47 | 17.68 | 2152 | NA | 0.47 | ADAMTS-1: oocyte maturation (r = 0.3673; P = 0.0300), good-quality embryo (r = 0.3472; P = 0.0410), fertilization (r = 0.1408; P = 0.3993), cleavage (r = 0.0749; P = 0.6548), blastocyst formation (r = 0.0673; P = 0.7239) |